#2 - AbCellera Biologics (NASDAQ:ABCL)
One of the most intriguing applications for artificial intelligence (AI) is in biotechnology. That’s why investors looking for stocks under $20 with 2x upside should consider AbCellera Biologics, Inc. (NASDAQ: ABCL). The company has an AI-powered engine for antibody drug discovery and development. AbCellera is looking for antibodies from natural immune responses that are pre-enriched for antibodies.
Cash is always a concern for clinical-stage biotech companies, but it appears to be less of a concern for AbCellera. At its current run rate, the company has five years of funding for its operations. AbCellera’s two lead candidates are currently in Investigational New Drug (IND)-enabling studies. And it is partnering with larger companies to get its pipeline candidates (which are still in the pre-clinical stage) through the clinical trial stage.
Despite the fact that the company will not generate revenue for several years, let alone post a profit, analysts give ABCL stock a Moderate Buy rating with a 178% upside, making it one of the largest potential gainers for stocks under $20.
About AbCellera Biologics
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Read More - Current Price
- $2.96
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $8.33 (181.5% Upside)
